Skip to content

Scholar Rock SRRK Investment and other (expense) income, net

Investment and other (expense) income, net at other companies

Insmed logo
InsmedINSM
$12.04M-13.4%

Other financials

Income statement

See full
Revenue-
Operating income-$102.0M-32.3%
Net income-$105.5M-41.2%
EPS (diluted)-$0.83-23.9%

Balance sheet

See full
Cash & equivalents$430.5M+212%
Total debt$205.7M+226%
Total equity$276.0M-11.6%
Total assets$535.3M+31.3%

Cash flow

See full
Operating cash flow-$82.1M-4.4%
CapEx$68.0K-74.9%
Free cash flow-$82.2M-4.1%

Valuation

See full
Market cap$5.67B+85.5%
Enterprise value$5.45B+82.6%
P/S170.9×

Profitability

See full
Operating margin-231.8%
Net margin-236.9%
FCF margin-309.1%

Returns & leverage

See full
Return on equity-138.9%+60.1pp
Debt / equity0.7×+0.5×
Current ratio8.6×-1.6×

Where this comes from

Reported directly by Scholar Rock in its filing.

Tagged under the XBRL concept us-gaap:InvestmentIncomeNonoperating.

The official record: Scholar Rock’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Scholar Rock's investment and other (expense) income, net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Scholar Rock's investment and other (expense) income, net?
Scholar Rock (SRRK) reported investment and other (expense) income, net of $2.94M in Q1 2026.
How has Scholar Rock's investment and other (expense) income, net changed year-over-year?
Scholar Rock's investment and other (expense) income, net decreased by 30.6% year-over-year, from $4.23M to $2.94M.
What does investment and other (expense) income, net mean?
This metric represents the net financial result of non-operating activities, including interest income earned on cash balances and interest expenses incurred on debt obligations. It reflects the company's ability to generate supplemental returns from its treasury management or the cost of its capital structure outside of core biopharmaceutical operations. Investors use this to assess the impact of financial management on the bottom line independent of R&D and commercial activities.